
Amneal Pharmaceuticals (AMRX) Stock Forecast & Price Target
Amneal Pharmaceuticals (AMRX) Analyst Ratings
Bulls say
Amneal Pharmaceuticals is attractive because its Affordable Medicines segment is shifting toward complex generics, injectables, and biosimilars that carry higher barriers to entry, less price erosion, and better margin durability, while still benefiting from a steady 20-30 new launches per year. The Specialty franchise adds another layer of upside, with CREXONT’s rapid uptake, roughly 400 new prescribers monthly, and management’s confidence in a 30%-40% U.S. market share path supporting sales growth, while BREKIYA is already outperforming expectations. In addition, AvKARE’s move away from lower-margin distribution toward higher-margin government sales helped gross margin rise 410bps in 2025, and the company’s 2026 sales and EBITDA estimates were raised to $3.24Bn and $812MM, respectively, reinforcing a durable growth and margin-expansion story.
Bears say
Amneal Pharmaceuticals is viewed negatively because its growth thesis depends on several execution-sensitive catalysts that are already showing strain, including uncertain XOLAIR biosimilar launch timing toward late 2027, second-to-market positioning, and reported biosimilar revenue that declined about 20% in 2025. The company’s operating cash flow outlook was reduced by $25MM at the midpoint to $325MM-$375MM, reflecting finished goods inventory investment and collections shifting into 1Q'27, while CREXONT underperformance and delayed generic launches could weaken the Affordable Medicines segment’s key growth lever. In addition, the expectation that RYTARY faces generic competition in 2027 raises the risk of faster revenue and EBIT erosion, and the need for a step-change in biosimilar growth by 2030 makes the current trend look insufficient.
This aggregate rating is based on analysts' research of Amneal Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Amneal Pharmaceuticals (AMRX) Analyst Forecast & Price Prediction
Start investing in Amneal Pharmaceuticals (AMRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Amneal Pharmaceuticals (AMRX) Forecast
Amneal Pharmaceuticals (AMRX) Analyst Forecast & Price Prediction
Start investing in Amneal Pharmaceuticals (AMRX)
Order type
Buy in
Order amount
Est. shares
0 shares